Susquehanna International Group’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-151,200
| Closed | -$3.57M | – | 13725 |
|
|
2023
Q4 | $3.57M | Sell |
151,200
-155,800
| -51% | -$2.77M | ﹤0.01% | 4291 |
|
|
2023
Q3 | $4.58M | Buy |
307,000
+292,500
| +2,017% | +$3.88M | ﹤0.01% | 3687 |
|
|
2023
Q2 | $159K | Sell |
14,500
-21,700
| -60% | -$202K | ﹤0.01% | 10519 |
|
|
2023
Q1 | $316K | Buy |
36,200
+20,400
| +129% | +$163K | ﹤0.01% | 9610 |
|
|
2022
Q4 | $99.1K | Sell |
15,800
-3,300
| -17% | -$12.5K | ﹤0.01% | 10970 |
|
|
2022
Q3 | $67K | Sell |
19,100
-5,000
| -21% | -$18K | ﹤0.01% | 12015 |
|
|
2022
Q2 | $71K | Sell |
24,100
-35,000
| -59% | -$83.6K | ﹤0.01% | 11762 |
|
|
2022
Q1 | $184K | Buy |
59,100
+14,200
| +32% | +$44.7K | ﹤0.01% | 11339 |
|
|
2021
Q4 | $152K | Sell |
44,900
-133,700
| -75% | -$508K | ﹤0.01% | 11781 |
|
|
2021
Q3 | $652K | Sell |
178,600
-96,300
| -35% | -$379K | ﹤0.01% | 8701 |
|
|
2021
Q2 | $1.2M | Buy |
274,900
+22,600
| +9% | +$100K | ﹤0.01% | 7255 |
|
|
2021
Q1 | $1.15M | Buy |
252,300
+25,300
| +11% | +$136K | ﹤0.01% | 7365 |
|
|
2020
Q4 | $1.3M | Buy |
227,000
+129,100
| +132% | +$977K | ﹤0.01% | 6068 |
|
|
2020
Q3 | $709K | Sell |
97,900
-158,500
| -62% | -$848K | ﹤0.01% | 6938 |
|
|
2020
Q2 | $895K | Buy |
+256,400
| New | +$740K | ﹤0.01% | 6169 |
|
|
2019
Q3 | – | Sell |
-31,000
| Closed | -$222K | – | 10992 |
|
|
2019
Q2 | $222K | Sell |
31,000
-20,700
| -40% | -$234K | ﹤0.01% | 8925 |
|
|
2019
Q1 | $687K | Buy |
51,700
+25,700
| +99% | +$273K | ﹤0.01% | 5708 |
|
|
2018
Q4 | $205K | Sell |
26,000
-16,700
| -39% | -$159K | ﹤0.01% | 7699 |
|
|
2018
Q3 | $473K | Buy |
42,700
+6,400
| +18% | +$79.5K | ﹤0.01% | 6635 |
|
|
2018
Q2 | $487K | Buy |
36,300
+16,300
| +82% | +$204K | ﹤0.01% | 6845 |
|
|
2018
Q1 | $260K | Buy |
+20,000
| New | +$248K | ﹤0.01% | 7866 |
|
|
2017
Q4 | – | Sell |
-15,400
| Closed | -$124K | – | 10065 |
|
|
2017
Q3 | $124K | Buy |
+15,400
| New | +$104K | ﹤0.01% | 8284 |
|
Other funds holding CBAY
Susquehanna International Group's CBAY Position: Q1 2024 in Review
Susquehanna International Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 68,457 shares — an estimated $1.62M sold.
Susquehanna International Group first reported a position in CBAY in Q1 2015 and held it in 22 quarters. The position peaked at $10.3M in Q1 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Susquehanna International Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Susquehanna International Group sold 68,457 Cymabay Therapeutics shares in Q1 2024, an estimated $1.62M.
- Susquehanna International Group first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 22 quarters.
- Susquehanna International Group's Cymabay Therapeutics position peaked at $10.3M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.